Novocure Ltd (NASDAQ:NVCR) General Counsel Todd Christopher Longsworth sold 15,000 shares of the business’s stock in a transaction dated Wednesday, January 16th. The shares were sold at an average price of $45.15, for a total value of $677,250.00. Following the completion of the transaction, the general counsel now directly owns 36,305 shares of the company’s stock, valued at approximately $1,639,170.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Todd Christopher Longsworth also recently made the following trade(s):

  • On Wednesday, January 9th, Todd Christopher Longsworth sold 15,000 shares of Novocure stock. The shares were sold at an average price of $40.15, for a total value of $602,250.00.

Shares of NVCR stock opened at $46.45 on Monday. The stock has a market capitalization of $4.32 billion, a PE ratio of -66.36 and a beta of 2.86. The company has a quick ratio of 5.72, a current ratio of 6.17 and a debt-to-equity ratio of 1.30. Novocure Ltd has a 52-week low of $19.20 and a 52-week high of $53.70.

Novocure (NASDAQ:NVCR) last released its quarterly earnings results on Thursday, October 25th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. The company had revenue of $64.76 million during the quarter, compared to analysts’ expectations of $65.61 million. Novocure had a negative return on equity of 52.72% and a negative net margin of 25.37%. As a group, equities research analysts expect that Novocure Ltd will post -0.68 earnings per share for the current fiscal year.

Several equities analysts have recently issued reports on the company. BidaskClub raised Novocure from a “hold” rating to a “buy” rating in a report on Friday, January 11th. ValuEngine raised Novocure from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 10th. Zacks Investment Research cut Novocure from a “hold” rating to a “sell” rating in a report on Saturday, December 29th. Mizuho reissued a “buy” rating and issued a $51.00 price objective on shares of Novocure in a report on Thursday, December 6th. Finally, Wells Fargo & Co cut Novocure from an “outperform” rating to a “market perform” rating in a report on Friday, November 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Novocure currently has a consensus rating of “Buy” and a consensus target price of $48.00.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its holdings in Novocure by 29.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 500 shares during the period. Envestnet Asset Management Inc. acquired a new position in Novocure in the 2nd quarter worth about $135,000. WINTON GROUP Ltd acquired a new position in Novocure in the 2nd quarter worth about $202,000. Oppenheimer & Co. Inc. acquired a new position in Novocure in the 3rd quarter worth about $210,000. Finally, Evercore Wealth Management LLC acquired a new position in Novocure in the 3rd quarter worth about $220,000. 58.58% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Novocure Ltd (NVCR) General Counsel Sells $677,250.00 in Stock” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://theolympiareport.com/2019/01/21/insider-selling-novocure-ltd-nvcr-general-counsel-sells-677250-00-in-stock.html.

Novocure Company Profile

Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.

Recommended Story: How to execute a trade ex-dividend strategy?

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.